Abstract
Recent electrophysiological studies have clarified that endogenous cannabinoids (endocannabinoids) mediate retrograde signals from postsynaptic neurons to presynaptic terminals in the CNS. Endocannabinoids can be released from postsynaptic neurons following depolarization-induced elevation of intracellular Ca2+ concentration. The released endocannabinoids act retrogradely onto presynaptic cannabinoid CB1 receptors and suppress inhibitory or excitatory neurotransmitter release. This type of modulation has been termed depolarizationinduced suppression of inhibition (DSI) or excitation (DSE). Endocannabinoid release and resultant retrograde suppression of transmitter release are also triggered by activation of group I metabotrophic glutamate receptors (mGluRs) or muscarinic acetylcholine receptors (mAChRs) in the postsynaptic neurons. This pathway can work independently of the depolarization-induced mechanism, because group I mGluR activation can produce endocannabinoids when the postsynaptic neuron is loaded with the fast Ca2+ buffer BAPTA. Nevertheless, evidence suggests that these two pathways for endocannabinoid production can work cooperatively in neurons. It is shown that DSI is enhanced significantly when group I mGluRs, or mAChRs is activated simultaneously by its specific agonists. This enhancement is much more prominent than what is expected from the simple summation of depolarization-induced and group I mGluR / mAChR-induced endocannabinoid release. Activation of group I mGluRs or mAChRs causes no significant change in depolarization-induced Ca2+ transients, indicating that the enhanced DSI does not result from the augmentation of Ca2+ influx. The CB1, group I mGluRs, mAChRs and voltage-gated Ca2+ channels are all expressed widely in the CNS. Thus, the endocannabinoid-mediated retrograde modulation is an important and widespread mechanism for the regulation of synaptic transmission in the CNS.
Keywords: endogenous cannabinoid, retrograde signal, synapse, cb1 receptor, dsi, metabotropic glutamate receptor, muscarinic acetylcholine receptor
Current Neuropharmacology
Title: Retrograde Modulation of Synaptic Transmission Mediated by Endogenous Cannabinoids
Volume: 2 Issue: 1
Author(s): M. Kano, T. Ohno-Shosaku, T. Maejima, T. Yoshida and K. Hashimoto
Affiliation:
Keywords: endogenous cannabinoid, retrograde signal, synapse, cb1 receptor, dsi, metabotropic glutamate receptor, muscarinic acetylcholine receptor
Abstract: Recent electrophysiological studies have clarified that endogenous cannabinoids (endocannabinoids) mediate retrograde signals from postsynaptic neurons to presynaptic terminals in the CNS. Endocannabinoids can be released from postsynaptic neurons following depolarization-induced elevation of intracellular Ca2+ concentration. The released endocannabinoids act retrogradely onto presynaptic cannabinoid CB1 receptors and suppress inhibitory or excitatory neurotransmitter release. This type of modulation has been termed depolarizationinduced suppression of inhibition (DSI) or excitation (DSE). Endocannabinoid release and resultant retrograde suppression of transmitter release are also triggered by activation of group I metabotrophic glutamate receptors (mGluRs) or muscarinic acetylcholine receptors (mAChRs) in the postsynaptic neurons. This pathway can work independently of the depolarization-induced mechanism, because group I mGluR activation can produce endocannabinoids when the postsynaptic neuron is loaded with the fast Ca2+ buffer BAPTA. Nevertheless, evidence suggests that these two pathways for endocannabinoid production can work cooperatively in neurons. It is shown that DSI is enhanced significantly when group I mGluRs, or mAChRs is activated simultaneously by its specific agonists. This enhancement is much more prominent than what is expected from the simple summation of depolarization-induced and group I mGluR / mAChR-induced endocannabinoid release. Activation of group I mGluRs or mAChRs causes no significant change in depolarization-induced Ca2+ transients, indicating that the enhanced DSI does not result from the augmentation of Ca2+ influx. The CB1, group I mGluRs, mAChRs and voltage-gated Ca2+ channels are all expressed widely in the CNS. Thus, the endocannabinoid-mediated retrograde modulation is an important and widespread mechanism for the regulation of synaptic transmission in the CNS.
Export Options
About this article
Cite this article as:
Kano M., Ohno-Shosaku T., Maejima T., Yoshida T. and Hashimoto K., Retrograde Modulation of Synaptic Transmission Mediated by Endogenous Cannabinoids, Current Neuropharmacology 2004; 2 (1) . https://dx.doi.org/10.2174/1570159043476945
DOI https://dx.doi.org/10.2174/1570159043476945 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Atrial Fibrillation with a Focus on Oral Antiarrhythmic Therapy
Current Drug Therapy Protein Geranylgeranyltransferase Type 1 as a Target in Cancer
Current Cancer Drug Targets Mechanisms Underlying the Hepatotoxic Effects of Ecstasy
Current Pharmaceutical Biotechnology Beneficial Effects of Statins on Endothelial Dysfunction and Vascular Stiffness
Current Vascular Pharmacology Avoidance of Aβ[25-35] / (H2O2) -Induced Apoptosis in Lymphocytes by the Cannabinoid Agonists CP55, 940 and JWH-015 via Receptor-Independent and PI3K-Dependent Mechanisms: Role of NF- κB and p53
Medicinal Chemistry Cyclin-Dependent Kinase Inhibition by Flavoalkaloids
Mini-Reviews in Medicinal Chemistry Applications of Aptamers in Targeted Imaging: State of the Art
Current Topics in Medicinal Chemistry Alkaloids Pharmacological Activities - Prospects for the Development of Phytopharmaceuticals for Neurodegenerative Diseases
Current Pharmaceutical Biotechnology Neuronal Acetylcholine Nicotinic Receptors as New Targets for Lung Cancer Treatment
Current Pharmaceutical Design <i>Thespesia populnea</i>: An Ethnomedicinal, Phytochemical and Pharmacological Review
The Natural Products Journal Identification of Cancerlectins by Split Bi-profile Bayes Feature Extraction
Current Proteomics An Economic Evaluation of Treatments for HIV-Associated Facial Lipoatrophy: A Cost-Utility Analysis
Current HIV Research Targeting of Leukemia-Initiating Cells to Develop Curative Drug Therapies: Straightforward but Nontrivial Concept
Current Cancer Drug Targets Lycopene Protects Liver Against Ulcerative Colitis
Current Drug Therapy Mechanistic Studies of the Process of Amyloid Fibrils Formation by the Use of Peptide Fragments and Analogues: Implications for the Design of Fibrillization Inhibitors
Current Medicinal Chemistry Transcription Factors as Therapeutic Targets in CNS Disorders
Recent Patents on CNS Drug Discovery (Discontinued) Meningioma in an Elderly Presenting as Psychosis: A Case Report
Clinical Cancer Drugs Neurodegeneration and Neuroprotection in Multiple Sclerosis
Current Pharmaceutical Design Sustained Release In Situ Implant of Arteether Based on Transition of Smedds into Lyotropic Liquid Crystalline Phases
Current Nanomedicine Evaluation of in vivo Anti-inflammatory and Analgesic Activities of Novel Derivatives of Ugi-4CR
Mini-Reviews in Medicinal Chemistry